Are opioids better than nonopioids to improve pain?
President Donald Trump was expected to announce a new plan to combat the opioid crisis, even as a recent study found that prescription opioids were not as effective as over-the-counter medications for pain management.
In the midst of President Donald Trump's proposed new plan to combat opioid abuse, a recent study found that prescription opioids were not as effective as over-the-counter (OTC) medications for pain management.
President Trump's plan, unveiled on March 19, includes: cutting opioid prescription fills by one-third within 3 years, providing treatment and recovery support services for addicts, and seeking the death penalty for opioid traffickers, NPR reported.
In an appearance in New Hampshire on Monday, Trump was expected to propose that drug traffickers receive the death penalty when appropriate, along with a plan for expanded access to treatment and recovery programs and enhanced public awareness.
Related: FDA warns about opioid-containing supplement
Meanwhile, in the large pain study, published in the March 6, 2018, issue of JAMA, pain intensity was significantly better in patients taking OTC medications such as acetaminophen versus prescription opioids such as Vicodin.
The study involved 240 Veterans Affairs' patients who had moderate to severe chronic back pain, or hip or knee osteoarthritis pain, despite analgesic use.
The researchers compared patients’ pain intensity, pain-related function, and adverse effects between opioids such as morphine, oxycodone or fentanyl patches versus nonopioids, including generic Tylenol, ibuprofen and prescription nerve and muscle pain drugs.
Related: FDA takes tough stance on kids’ opioid cold meds
While the two groups-those taking prescription opioids and those taking non-opioid medications-did not significantly differ on pain-related function over a 12-month period, pain intensity was significantly better in the non-opioid group. The Brief Pain Inventory (BPI) severity was 4.0 for the opioid group and 3.5 for the nonopioid group.
“Treatment with opioids was not superior to treatment with nonopioid medications for improving pain-related function over 12 months. Results do not support initiation of opioid therapy for moderate to severe chronic back pain or hip or knee osteoarthritis pain,” the researchers wrote.
Adverse medication-related symptoms were significantly more common in the opioid group over 12 months:1.8 in the opioid group versus 0.9 in the nonopioid group.
Read more: DEA tightens fentanyl scheduling
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
August 1st 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
August 1st 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
August 1st 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More
